Kamada

Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020

Retrieved on: 
Wednesday, August 5, 2020
Kamada, Rehovot, Science and technology in Israel, Tel Aviv Stock Exchange, Conference call, Economy of Israel, Western Asia, Companies

REHOVOT, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the second quarter ended June 30, 2020, prior to the open of the U.S. financial markets on Wednesday, August 12, 2020.

Key Points: 
  • REHOVOT, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the second quarter ended June 30, 2020, prior to the open of the U.S. financial markets on Wednesday, August 12, 2020.
  • Kamada management will host an investment community conference call on Wednesday, August 12, at 8:30am Eastern Time to discuss these results and answer questions.
  • Shareholders and other interested parties may participate in the conference call by dialing 855-327-6837 (from within the U.S.), 1-809-458-327 (from Israel), or 631-891-4304 (International) and entering the conference identification number: 10010379.
  • The call will also be webcast live on the Internet on the Companys website at www.kamada.com .

Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel

Retrieved on: 
Wednesday, June 17, 2020
Anatomy, Body fluids, Transfusion medicine, Kamada, Rehovot, Science and technology in Israel, Branches of biology, Blood products, Blood plasma

Kamada completed manufacturing of the first batch of its plasma-derived IgG product for COVID-19 utilizing the Companys approved proprietary IgG platform technology, and additional production is ongoing.

Key Points: 
  • Kamada completed manufacturing of the first batch of its plasma-derived IgG product for COVID-19 utilizing the Companys approved proprietary IgG platform technology, and additional production is ongoing.
  • Kedrion is collecting the plasma, through its plasma business unit, KEDPLASMA, at 23 FDA-approved centers across the United States.
  • To the best of our knowledge, Kamada is the first company globally to complete manufacturing of a plasma-derived IgG product for the treatment of COVID-19.
  • The Company has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency.

Kamada to Announce First Quarter Ended March 31, 2020 Financial Results and Host Conference Call on May 18, 2020

Retrieved on: 
Monday, May 11, 2020
Rehovot, Kamada, Science and technology in Israel, Tel Aviv Stock Exchange, Tase, Conference call, Economy of Israel, Companies, Western Asia

REHOVOT, Israel, May 11, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31, 2020, prior to the open of the U.S. financial markets on Monday, May 18, 2020.

Key Points: 
  • REHOVOT, Israel, May 11, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31, 2020, prior to the open of the U.S. financial markets on Monday, May 18, 2020.
  • Kamada management will host an investment community conference call on Monday, May 18, at 8:30am Eastern Time to discuss these results and answer questions.
  • Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 201-689-8263 (International) and entering the conference identification number: 13699990.
  • The call will also be webcast live on the Internet on the Companys website at www.kamada.com .

Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel Announce Global Collaboration to Speed New Anti-COVID Plasma-Based Treatment

Retrieved on: 
Wednesday, April 29, 2020
Kamada, Rehovot, Science and technology in Israel, Virus, Economy of Israel, Life sciences, Companies

Under the newly announced agreement Kedrion will provide plasma collected at its KEDPLASMA centers from donors in both Europe and the U.S. who have recovered from the virus.

Key Points: 
  • Under the newly announced agreement Kedrion will provide plasma collected at its KEDPLASMA centers from donors in both Europe and the U.S. who have recovered from the virus.
  • Under the terms of the agreement, Kamada is responsible for product development, manufacturing, clinical development (with Kedrion's support) and regulatory submissions.
  • Kamada will distribute in all other territories, while marketing rights for the product in China will be shared by both companies.
  • The Kedrion CEO said the company is already in contact with the Italian health authorities while Kamada is in touch with the Israeli authorities.

Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel Announce Global Collaboration to Speed New Anti-COVID Plasma-Based Treatment

Retrieved on: 
Wednesday, April 29, 2020
Kamada, Rehovot, Science and technology in Israel, Virus, Economy of Israel, Life sciences, Companies

Under the newly announced agreement Kedrion will provide plasma collected at its KEDPLASMA centers from donors in both Europe and the U.S. who have recovered from the virus.

Key Points: 
  • Under the newly announced agreement Kedrion will provide plasma collected at its KEDPLASMA centers from donors in both Europe and the U.S. who have recovered from the virus.
  • Under the terms of the agreement, Kamada is responsible for product development, manufacturing, clinical development (with Kedrion's support) and regulatory submissions.
  • Kamada will distribute in all other territories, while marketing rights for the product in China will be shared by both companies.
  • The Kedrion CEO said the company is already in contact with the Italian health authorities while Kamada is in touch with the Israeli authorities.

Kamada and Kedrion Biopharma Announce Global Collaboration for the Development, Manufacturing and Distribution of a Plasma-Derived Anti-SARS-CoV-2 (COVID-19) Polyclonal Immunoglobulin Product

Retrieved on: 
Monday, April 27, 2020
Viruses, Medicine, Branches of biology, Animal virology, Zoonoses, Severe acute respiratory syndrome-related coronavirus, Coronavirus, Severe acute respiratory syndrome, Kamada, Antibody

Kamada is responsible for product development, manufacturing, clinical development, with Kedrions support, and regulatory submissions.

Key Points: 
  • Kamada is responsible for product development, manufacturing, clinical development, with Kedrions support, and regulatory submissions.
  • Kamada will also assume distribution responsibility in all territories outside of those Kedrion is responsible for.
  • In light of the current global coronavirus outbreak, Kedrion and Kamada have quickly focused their efforts on developing and manufacturing a potentially safe and effective treatment, said Paolo Marcucci, Chief Executive Officer of Kedrion.
  • As previously reported, we initiated the development of an Anti-SARS-CoV-2 polyclonal immunoglobulin and intend to begin clinical manufacturing of the product shortly.

Kamada Files Annual Report for the Year Ended December 31, 2019

Retrieved on: 
Wednesday, February 26, 2020
Life sciences, Articles, Biotechnology, Kamada, Rehovot, Science and technology in Israel, Financial statements, SEC filing, Audit, Biopharmaceutical

The annual report, including the Companys audited consolidated financial statements, can be accessed via the SECs website at https://www.sec.gov/edgar.shtml , as well as under the SEC Filings section on Kamadas investor relations website at https://www.kamada.com/ .

Key Points: 
  • The annual report, including the Companys audited consolidated financial statements, can be accessed via the SECs website at https://www.sec.gov/edgar.shtml , as well as under the SEC Filings section on Kamadas investor relations website at https://www.kamada.com/ .
  • The Company will deliver a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request.
  • Kamada Ltd. (the Company) is a plasma-derived biopharmaceutical company focused on orphan indications, with an existing marketed product portfolio and a late-stage product pipeline.
  • The Companys flagship product is GLASSIA (GLASSIA), the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. FDA.

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020

Retrieved on: 
Wednesday, February 5, 2020
Companies, Kamada, Rehovot, Science and technology in Israel, Life sciences, Health, Pharmaceutical industry in China, Takeda Pharmaceutical Company

Kamada management will host an investment community conference call on Wednesday, February 12, at 8:30am Eastern Time to discuss these results and answer questions.

Key Points: 
  • Kamada management will host an investment community conference call on Wednesday, February 12, at 8:30am Eastern Time to discuss these results and answer questions.
  • The call will also be webcast live on the Internet on the Companys website at www.kamada.com .
  • Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a late-stage product pipeline.
  • Kamada markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited and in other counties through local distributors.

Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund

Retrieved on: 
Tuesday, January 21, 2020
Economy, Finance, Money, Investment, Financial markets, Equity securities, Kamada, Rehovot, Science and technology in Israel, Private placement, Tel Aviv Stock Exchange, Security

REHOVOT, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that it has entered into a securities purchase agreement with FIMI Opportunity Funds (FIMI), the leading private equity investor in Israel, to purchase $25 million of its ordinary shares in a private placement.

Key Points: 
  • REHOVOT, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that it has entered into a securities purchase agreement with FIMI Opportunity Funds (FIMI), the leading private equity investor in Israel, to purchase $25 million of its ordinary shares in a private placement.
  • Proceeds from the private placement are expected to be used to finance the Companys growth plans and execution of strategic business opportunities.
  • The securities offered to FIMI have not been registered under the Securities Act of 1933, as amended.
  • We are pleased to enhance our commitment to Kamada through this important financing, said Lilach Asher-Topilsky, a Senior Partner at FIMI.

Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product

Retrieved on: 
Monday, December 9, 2019
Kamada, Rehovot, Science and technology in Israel, Articles, Health, Food and Drug Administration, Life sciences

Following the execution of the required technology transfer from the current manufacturer, and pending obtaining all required FDA approvals, Kamada is expected to commence commercial manufacturing of the product in early 2023.

Key Points: 
  • Following the execution of the required technology transfer from the current manufacturer, and pending obtaining all required FDA approvals, Kamada is expected to commence commercial manufacturing of the product in early 2023.
  • This binding term sheet supports our strategy to leverage our experience and available manufacturing capacity at our FDA-approved manufacturing facility to initiate the production of additional plasma-derived products following the transition of GLASSIA manufacturing to Takeda during 2021, said Amir London, CEO of Kamada.
  • Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a late-stage product pipeline.
  • The Companys flagship product is GLASSIA, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration.